Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans
Allergology International · 2024
DOI: 10.1016/j.alit.2023.10.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergology International, 2024. Verfasst von Keiko Komatsuzaki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: komatsuzaki.hsc@tmd.ac.jp. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Seasonal, Food Hypersensitivity, Fluorocarbons, Mannans. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tokyo Medical and Dental University.
Abstract (Originalsprache)
BACKGROUND: Allergen immunotherapy (AIT) is the only disease-modifying treatment for immunoglobulin (Ig) E-mediated allergy. Owing to the high prevalence and early onset of hay fever and pollen-food allergy syndrome (PFAS), a safer and simpler treatment method than conventional AIT is needed. To develop a local nasal immunotherapy using an ointment containing hypoallergenic pollen and assess its efficacy in mice and healthy humans. METHODS: Hypoallergenicity was achieved by combining pollen and galactomannan through the Maillard reaction to create birch pollen-galactomannan conjugate (BP-GMC). The binding of galactomannan to Bet v 1 was confirmed using electrophoresis and Western blotting (WB). Binding of specific IgE antibodies to BP-GMC was verified using enzyme-linked immunosorbent assay (ELISA) and basophil activation test (BAT). The localization of BP-GMC absorption was confirmed using a BALB/c mouse model. BP-GMC mixed with white petrolatum was intranasally administered to 10 healthy individuals (active drugs, 8; placebo, 2) for 14 days. RESULTS: In electrophoresis and WB, no 17-kDa band was observed. In ELISA and BAT, BP-GMC did not react to specific IgE but was bound to IgA and IgG. In the mouse model, BP-GMC was detected in nasopharyngeal-associated lymphoid tissues. In the active drug group, the salivary-specific IgA level significantly increased on day 15 (p = 0.0299), while the serum-specific IgG level significantly increased on day 85 (p = 0.0006). CONCLUSIONS: The BP-GMC ointment rapidly produced antagonistic antibodies against IgE; it is safe and easy to use and might serve as a therapeutic antigen for hay fever and PFAS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: komatsuzaki.hsc@tmd.ac.jp.
- Bio & Healthcare Business Division, Wako Filter Technology Co., Ltd., Ibaraki, Japan.
- Department of Otorhinolaryngology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Respiratory Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Clinical Biostatistics, Tokyo Medical and Dental University, Tokyo, Japan.
Förderung
- Tokyo Medical and Dental University
Zitieren
APA
Komatsuzaki, K., Kageshima, H., Sekino, Y., Suzuki, Y., Ugajin, T., Tamaoka, M., Hanazawa, R., Hirakawa, A., & Miyazaki, Y. (2024). Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans. Allergology International. https://doi.org/10.1016/j.alit.2023.10.007
Vancouver
Komatsuzaki K, Kageshima H, Sekino Y, Suzuki Y, Ugajin T, Tamaoka M, et al. Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans. Allergology International. 2024. doi:10.1016/j.alit.2023.10.007
BibTeX
@article{Komatsuzaki2024,
author = {Komatsuzaki, Keiko and Kageshima, Hiroki and Sekino, Yuki and Suzuki, Yasuhiro and Ugajin, Tsukasa and Tamaoka, Meiyo and Hanazawa, Ryoichi and Hirakawa, Akihiro and Miyazaki, Yasunari},
title = {Local nasal immunotherapy with birch pollen-galactomannan conjugate-containing ointment in mice and humans},
journal = {Allergology International},
year = {2024},
doi = {10.1016/j.alit.2023.10.007}
}
EUVIMED